Implementing Novel Agents in the Treatment of oHCM : compare

Expert cardiologists share approaches to implementing mavacamten and aficamten in the clinical treatment of oHCM.

Related Keywords

Massachusetts , United States , Anjali Owens , Andrew Wang , Milind Desai , James Januzzi , Heart Center , Risk Evaluation , Mitigation Strategies , Massachusetts General Heart Center , Nt Pro Bnp , Obstructive Hypertrophic Cardiomyopathy , Johcm , Left Ventricular Ejection Fraction , Cp450 , Atrial Fibrillation , Drug Interactions , Cardiac Myosin Inhibitors , Long Term Efficacy , Heart Failure , Disease Modifying Therapies ,